143 related articles for article (PubMed ID: 23161221)
21. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA
Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195
[TBL] [Abstract][Full Text] [Related]
22. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.
Sun L; Qian Q; Sun G; Mackey LV; Fuselier JA; Coy DH; Yu CY
J Drug Target; 2016; 24(2):169-77. PubMed ID: 26211366
[TBL] [Abstract][Full Text] [Related]
23. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
24. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Valentini A; Gravina P; Federici G; Bernardini S
Cancer Biol Ther; 2007 Feb; 6(2):185-91. PubMed ID: 17218782
[TBL] [Abstract][Full Text] [Related]
25. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
26. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Stauber RH; Knauer SK; Habtemichael N; Bier C; Unruhe B; Weisheit S; Spange S; Nonnenmacher F; Fetz V; Ginter T; Reichardt S; Liebmann C; Schneider G; Krämer OH
Oncotarget; 2012 Jan; 3(1):31-43. PubMed ID: 22289787
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Biran A; Brownstein M; Haklai R; Kloog Y
Int J Cancer; 2011 Feb; 128(3):691-701. PubMed ID: 20473860
[TBL] [Abstract][Full Text] [Related]
28. Wogonin inhibits the proliferation and invasion, and induces the apoptosis of HepG2 and Bel7402 HCC cells through NF‑κB/Bcl-2, EGFR and EGFR downstream ERK/AKT signaling.
Liu X; Tian S; Liu M; Jian L; Zhao L
Int J Mol Med; 2016 Oct; 38(4):1250-6. PubMed ID: 27499272
[TBL] [Abstract][Full Text] [Related]
29. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA
Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339
[TBL] [Abstract][Full Text] [Related]
30. Valproic acid downregulates NF-κB p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line.
Schwertheim S; Worm K; Schmid KW; Sheu-Grabellus SY
Horm Metab Res; 2014 Mar; 46(3):181-6. PubMed ID: 24526373
[TBL] [Abstract][Full Text] [Related]
31. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
32. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.
Wei M; Mao S; Lu G; Li L; Lan X; Huang Z; Chen Y; Zhao M; Zhao Y; Xia Q
BMC Cancer; 2018 Apr; 18(1):434. PubMed ID: 29665787
[TBL] [Abstract][Full Text] [Related]
33. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.
Zhang L; Wang G; Wang L; Song C; Leng Y; Wang X; Kang J
Mol Cell Biochem; 2012 Feb; 361(1-2):39-45. PubMed ID: 21959976
[TBL] [Abstract][Full Text] [Related]
34. Valproic Acid Synergizes With Cisplatin and Cetuximab
Iannelli F; Zotti AI; Roca MS; Grumetti L; Lombardi R; Moccia T; Vitagliano C; Milone MR; Ciardiello C; Bruzzese F; Leone A; Cavalcanti E; De Cecio R; Iachetta G; Valiante S; Ionna F; Caponigro F; Di Gennaro E; Budillon A
Front Cell Dev Biol; 2020; 8():732. PubMed ID: 33015030
[TBL] [Abstract][Full Text] [Related]
35. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
36. Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Xi W; Chen X; Sun J; Wang W; Huo Y; Zheng G; Wu J; Li Y; Yang A; Wang T
Med Sci Monit; 2018 Feb; 24():1034-1043. PubMed ID: 29457966
[TBL] [Abstract][Full Text] [Related]
37. Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model.
Cetinkaya M; Cansev M; Cekmez F; Tayman C; Canpolat FE; Kafa IM; Yaylagul EO; Kramer BW; Sarici SU
PLoS One; 2015; 10(5):e0126028. PubMed ID: 25938838
[TBL] [Abstract][Full Text] [Related]
38. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II.
Tsai C; Leslie JS; Franko-Tobin LG; Prasnal MC; Yang T; Vienna Mackey L; Fuselier JA; Coy DH; Liu M; Yu C; Sun L
Arch Gynecol Obstet; 2013 Aug; 288(2):393-400. PubMed ID: 23435724
[TBL] [Abstract][Full Text] [Related]
39. Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells.
Thotala D; Karvas RM; Engelbach JA; Garbow JR; Hallahan AN; DeWees TA; Laszlo A; Hallahan DE
Oncotarget; 2015 Oct; 6(33):35004-22. PubMed ID: 26413814
[TBL] [Abstract][Full Text] [Related]
40. The BH3-mimetic gossypol and noncytotoxic doses of valproic acid induce apoptosis by suppressing cyclin-A2/Akt/FOXO3a signaling.
Zhao GX; Xu LH; Pan H; Lin QR; Huang MY; Cai JY; Ouyang DY; He XH
Oncotarget; 2015 Nov; 6(36):38952-66. PubMed ID: 26517515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
